Introducing Faron
Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Our mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system.
The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through targeting myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
Our Purpose
Faron is at the forefront of immunology, developing a therapy designed to reprogram macrophages in the tumor microenvironment to better fight cancer.
We are a pioneer in targeting Clever-1, a novel immune checkpoint, so that tumors are turned from “cold” to hot and patients’ responses to standard therapy is improved, bolstering their quality of life.
Our lead asset
Bexmarilimab is being investigated in a Phase I/II clinical trial, BEXMAB, as a potential therapy for patients with hematological cancers in combination with standard of care. Bexmarilimab has also been investigated in the Phase I/II MATINS study in solid tumors.
Working today on tomorrow's breakthroughs
The field of immuno-oncology – now a mainstay of cancer treatment – has changed the way these diseases can be managed and yet not all patients benefit. Some tumor types show primary resistance, while others develop adaptive or secondary resistance. Generally, about 80% of cancer patients don’t respond to current immunotherapy treatments.
While the first wave of pioneering immunotherapies changed the face of cancer care, Faron’s ambition is to bring the promise of immunotherapy to a broader population.
Our commitment to patients and responsibility
Faron is unique in developing potentially powerful and brand-new agents that modulate the immune system in a completely different way from existing immunotherapy drugs. This commitment to improving patient lives is also embraced in the responsibility we have for our employees and for communities. Our responsibility is guided through our three priorities: Environmental, Social and Governance.